Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorShitara, Kohei
dc.contributor.authorDoi, Toshihiko
dc.contributor.authorHosaka, Hisashi
dc.contributor.authorThuss-Patience, Peter
dc.contributor.authorSantoro, Armando
dc.contributor.authorLongo-Muñoz, Federico
dc.contributor.authorAlsina Maqueda, Maria
dc.date.accessioned2022-09-09T07:12:40Z
dc.date.available2022-09-09T07:12:40Z
dc.date.issued2022-05
dc.identifier.citationShitara K, Doi T, Hosaka H, Thuss-Patience P, Santoro A, Longo F, et al. Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS). Gastric Cancer. 2022 May;25:586–97.
dc.identifier.issn1436-3305
dc.identifier.urihttp://hdl.handle.net/11351/8082
dc.descriptionGrups d'edat; Neoplàsies gastrointestinals; Trifluridina
dc.description.sponsorshipThis study was sponsored by Taiho Oncology, Inc., and Taiho Pharmaceuticals Co., Ltd. Professional medical writing and editorial assistance were provided by Vasupradha Vethantham, PhD, and Jennifer L. Robertson, PhD, at Ashfield MedComms, an Ashfield Health company, funded by Taiho Oncology, Inc.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesGastric Cancer;25
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectEsòfag - Càncer - Tractament
dc.subjectQuimioteràpia combinada
dc.subject.meshEsophageal Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.titleEfficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s10120-021-01271-9
dc.subject.decsneoplasias del esófago
dc.subject.decs/farmacoterapia
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.relation.publishversionhttps://doi.org/10.1007/s10120-021-01271-9
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Shitara K, Doi T] Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa-shi, Japan. [Hosaka H] Department of Gastroenterology, Gunma Prefectural Cancer Center, Ota, Gunma, Japan. [Thuss-Patience P] Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Charité-Universitätsmedizin Berlin, Berlin, Germany. [Santoro A] Department of Biomedical Sciences, Humanitas University, Milan, Italy. IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy. [Longo F] Medical Oncology, Hospital Universitario Ramon y Cajal, IRYCIS, CIBERONC, Madrid, Spain. [Alsina M] Servei d’Oncologia Mèdica, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid34997449
dc.identifier.wos000740186000001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple